-
11.发明授权公开(公告)号：US08143247B2
公开(公告)日：2012-03-27
申请号：US12437280
申请日：2009-05-07
Applicant: Gerd Munzert , Martin Steegmaier , Anke Baum
Inventor： Gerd Munzert , Martin Steegmaier , Anke Baum
IPC: A61K31/54 , A61K31/535 , A01N43/58 , C07D417/00
CPC classification number: A61K31/4985 , A61K31/435 , A61K31/4409 , A61K31/519
Abstract: Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
Abstract translation: 公开了用于治疗涉及细胞增殖的疾病的药物组合物。 还公开了治疗所述疾病的方法，包括共同给予式（I）的化合物1，其中基团L，R 1，R 2，R 3，R 4和R 5具有本文给出的含义和有效量的 活性化合物2和/或以放射疗法共同治疗，以提供添加剂和协同效应的比例，以及组合使用式（I）化合物1和有效量的活性化合物2和/ 或放射治疗用于制造相应的药物组合制剂。
-
公开(公告)号：US20110086842A1
公开(公告)日：2011-04-14
申请号：US12972976
申请日：2010-12-20
Applicant: Heinz STADTMUELLER , Harald ENGELHARDT , Martin STEEGMAIER , Anke BAUM , Ulrich GUERTLER , Andreas SCHOOP , Jens Juergen QUANT , Flavio SOLCA , Rudolf HAUPTMANN , Ulrich REISER , Stephan Karl ZAHN , Lars HERFURTH
Inventor： Heinz STADTMUELLER , Harald ENGELHARDT , Martin STEEGMAIER , Anke BAUM , Ulrich GUERTLER , Andreas SCHOOP , Jens Juergen QUANT , Flavio SOLCA , Rudolf HAUPTMANN , Ulrich REISER , Stephan Karl ZAHN , Lars HERFURTH
IPC: A61K31/553 , A61K31/506 , A61K31/5355 , A61P35/00 , A61P31/00 , A61P37/00
CPC classification number: C07D239/42 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D413/14 , C07D453/02 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/08 , C07D491/10
Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
Abstract translation: 本发明包括通式（1）的化合物，其中A，W，X，Y，Z，Ra，Rb，Rc，R 1和R 3如权利要求1中所定义，其适用于治疗以过量 或异常细胞增殖，以及其用于制备具有上述性质的药物组合物的用途。
-
13.发明授权Pyridodihydropyraziones, process for their manufacture and use thereof as medicaments 有权吡啶二氢吡喃硫酮，其制备方法和用途作为药物公开(公告)号：US07625899B2
公开(公告)日：2009-12-01
申请号：US11176737
申请日：2005-07-07
Applicant: Matthias Hoffmann , Matthias Grauert , Trixi Brandl , Martin Steegmaier , Rudolf Hauptmann
Inventor： Matthias Hoffmann , Matthias Grauert , Trixi Brandl , Martin Steegmaier , Rudolf Hauptmann
IPC: A01N43/58 , A01N43/60 , A61K31/50 , A61K31/495 , C07D237/00 , C07D239/00 , C07D241/00 , C07D471/00 , C07D487/00 , C07D491/00 , C07D495/00 , C07D497/00
CPC classification number: C07D471/04
Abstract: Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.
Abstract translation: 公开了吡啶二氢吡嗪酮化合物，其制备方法及其作为药物组合物的用途。 根据本发明的化合物对应于通式（I），而基团L，R 1，R 2，R 3，R 4和R 5可以具有权利要求书和说明书中给出的含义。
-
14.发明申请公开(公告)号：US20090238828A1
公开(公告)日：2009-09-24
申请号：US12437280
申请日：2009-05-07
Applicant: Gerd MUNZERT , Martin STEEGMAIER , Anke BAUM
Inventor： Gerd MUNZERT , Martin STEEGMAIER , Anke BAUM
IPC: A61K39/395 , A61K31/519 , A61K31/5377 , A61K31/55
CPC classification number: A61K31/4985 , A61K31/435 , A61K31/4409 , A61K31/519
Abstract: Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
Abstract translation: 公开了用于治疗涉及细胞增殖的疾病的药物组合物。 还公开了治疗所述疾病的方法，包括共同给予式（I）的化合物1，其中基团L，R 1，R 2，R 3，R 4和R 5具有本文给出的含义和有效量的 活性化合物2和/或以放射疗法共同治疗，以提供添加剂和协同效应的比例，以及组合使用式（I）化合物1和有效量的活性化合物2和/ 或放射治疗用于制造相应的药物组合制剂。
-
15.发明授权公开(公告)号：US07569561B2
公开(公告)日：2009-08-04
申请号：US11675936
申请日：2007-02-16
Applicant: Heinz Stadtmueller , Anke Baum , Guido Boehmelt , Harald Engelhardt , Jens Juergen Quant , Flavio Solca , Martin Steegmaier , Stephan Karl Zahn
Inventor： Heinz Stadtmueller , Anke Baum , Guido Boehmelt , Harald Engelhardt , Jens Juergen Quant , Flavio Solca , Martin Steegmaier , Stephan Karl Zahn
IPC: C07D403/12 , C07D413/12 , C07D498/04 , C07D487/04 , A61K31/551 , A61K31/553 , A61P29/00 , A61P35/00 , A61P37/00
CPC classification number: C07D498/04 , C07D403/12 , C07D413/12 , C07D487/04
Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R6, X and Y are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, as well as the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.
Abstract translation: 本发明包括通式（1）的化合物，其中R 1至R 6，X和Y如权利要求1中所定义，其适用于治疗以过度或异常细胞增殖为特征的疾病，以及其用于制备 具有上述性质的药物组合物。
-
Patent Agency Ranking
16.发明申请公开(公告)号：US20080319193A1
公开(公告)日：2008-12-25
申请号：US12192448
申请日：2008-08-15
Applicant: Matthias GRAUERT , Matthias HOFFMANN , Martin STEEGMAIER , Flavio SOLCA , Jens Juergen QUANT
Inventor： Matthias GRAUERT , Matthias HOFFMANN , Martin STEEGMAIER , Flavio SOLCA , Jens Juergen QUANT
IPC: C07D475/00
CPC classification number: C07D295/155 , C07D487/04 , Y02P20/55
Abstract: Disclosed are new dihydropteridinones of the formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings provided herein, the isomers thereof, processes for preparing these dihydropteridinones and their use as pharmaceutical compositions.
-
公开(公告)号：US20080221099A1
公开(公告)日：2008-09-11
申请号：US12120740
申请日：2008-05-15
Applicant: Gerd Munzert , Martin Steegmaier
Inventor： Gerd Munzert , Martin Steegmaier
IPC: A61K31/519 , A61K31/5377 , A61P35/04 , A61P31/10
CPC classification number: A61K31/525 , A61K31/5377
Abstract: Disclosed is the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.
Abstract translation: 公开了通式（1）的化合物，任选以其互变异构体，外消旋体，对映异构体，非对映体及其混合物的形式的用途，并且任选呈药理学上可接受的酸加成盐，溶剂化物，水合物，多晶型物，生理功能 衍生物或前体药物，用于通过抑制作为有丝分裂调节剂的马球状激酶来制备用于治疗特征在于人或非人哺乳动物体内异常细胞增殖的疾病的药物组合物。
-
公开(公告)号：US20060074088A1
公开(公告)日：2006-04-06
申请号：US11188926
申请日：2005-07-25
Applicant: Gerd Munzert , Martin Steegmaier
Inventor： Gerd Munzert , Martin Steegmaier
IPC: A61K31/525
CPC classification number: A61K31/525 , A61K31/5377
Abstract: Disclosed is the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.
Abstract translation: 公开了通式（1）的化合物，任选以其互变异构体，外消旋体，对映异构体，非对映体及其混合物的形式的用途，并且任选呈药理学上可接受的酸加成盐，溶剂化物，水合物，多晶型物，生理功能 衍生物或前体药物，用于通过抑制作为有丝分裂调节剂的马球状激酶来制备用于治疗特征在于人或非人哺乳动物体内异常细胞增殖的疾病的药物组合物。
-
19.发明申请New dihydropteridione derivatives, process for their manufacture and their use as medicament 有权新的二氢二萜衍生物，其制备方法及其作为药物的用途公开(公告)号：US20060046989A1
公开(公告)日：2006-03-02
申请号：US11210379
申请日：2005-08-24
Applicant: Matthias Grauert , Matthias Hoffmann , Martin Steegmaier , Flavio Solca , Jens Juergen Quant
Inventor： Matthias Grauert , Matthias Hoffmann , Martin Steegmaier , Flavio Solca , Jens Juergen Quant
IPC: A61K31/525 , C07D475/02
CPC classification number: C07D295/155 , C07D487/04 , Y02P20/55
Abstract: Disclosed are new dihydropteridinones of the formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings provided herein, the isomers thereof, processes for preparing these dihydropteridinones and their use as pharmaceutical compositions.
Abstract translation: 公开了式（I）的新的二氢蝶啶酮，其中基团L，R 1，R 2，R 3，R 4， ＆lt;＆gt;和＆lt; 5＆gt;具有本文提供的含义，其异构体，制备这些二氢蝶啶烷的方法及其作为药物组合物的用途。
-
20.发明申请New 6-formyl-tetrahydropteridines, process for their manufacture and use thereof as medicaments 有权新的6-甲酰基 - 四氢ter啶，其制备方法和用途作为药物公开(公告)号：US20060014751A1
公开(公告)日：2006-01-19
申请号：US11179234
申请日：2005-07-12
Applicant: Matthias Hoffmann , Matthias Grauert , Martin Steegmaier , Flavio Solca
Inventor： Matthias Hoffmann , Matthias Grauert , Martin Steegmaier , Flavio Solca
IPC: C07D475/02 , A61K31/525
CPC classification number: C07D475/00
Abstract: Disclosed are 6-formyl-tetrahydropteridines of the formula (I) wherein the groups R1 to R6 have the meanings given in the claims and specification, the isomers thereof, methods of preparing these 6-formyl-tetrahydropteridines and their use as medicaments.
Abstract translation: 公开了式（I）的6-甲酰基 - 四氢喋啶，其中基团R 1至R 6具有权利要求书和说明书中给出的含义，其异构体，方法 制备这些6-甲酰基 - 四氢喋啶及其作为药物的用途。
-
-
-
-
-
-
-
-
-
Search Results
61
records
(took 0.039 seconds)
